Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more
Indivior PLC (INDV) - Net Assets
Latest net assets as of June 2025: GBX-258.00 Million GBX
Based on the latest financial reports, Indivior PLC (INDV) has net assets worth GBX-258.00 Million GBX as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX1.45 Billion) and total liabilities (GBX1.71 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX-258.00 Million |
| % of Total Assets | -17.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | -524.39% |
| 10-Year Change | N/A |
| Growth Volatility | 128.1 |
Indivior PLC - Net Assets Trend (2011–2024)
This chart illustrates how Indivior PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Indivior PLC (2011–2024)
The table below shows the annual net assets of Indivior PLC from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX-348.00 Million | -3063.64% |
| 2023-12-31 | GBX-11.00 Million | -121.57% |
| 2022-12-31 | GBX51.00 Million | -74.88% |
| 2021-12-31 | GBX203.00 Million | +147.56% |
| 2020-12-31 | GBX82.00 Million | -60.77% |
| 2019-12-31 | GBX209.00 Million | +216.67% |
| 2018-12-31 | GBX66.00 Million | +132.51% |
| 2017-12-31 | GBX-203.00 Million | +31.19% |
| 2016-12-31 | GBX-295.00 Million | -5.73% |
| 2015-12-31 | GBX-279.00 Million | +41.26% |
| 2014-12-31 | GBX-475.00 Million | -619.70% |
| 2013-12-31 | GBX-66.00 Million | -145.52% |
| 2012-12-31 | GBX145.00 Million | -42.91% |
| 2011-12-31 | GBX254.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Indivior PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45300000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX62.00 Million | % |
| Other Components | GBX44.00 Million | % |
| Total Equity | GBX-348.00 Million | 100.00% |
Indivior PLC Competitors by Market Cap
The table below lists competitors of Indivior PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LUMBER LIQ HLDG
BE:LKU
|
$187.95K |
|
Gabelli Global Utility & Income Tr
NYSE MKT:GLU
|
$188.10K |
|
Strive Total Return Bond ETF
NYSE:STXT
|
$188.14K |
|
EDENRED (QSV.SG)
STU:QSV
|
$188.28K |
|
Maj Invest Glob Akt non fossil
CO:MAJGANF
|
$187.91K |
|
Entergy Arkansas LLC Deb 2066
NYSE:EAI
|
$187.85K |
|
BROWN NON VTG-B - Dusseldorf Stock Exchang
DU:BF5B
|
$187.79K |
|
TDSPU
OTCGREY:TDSPU
|
$187.74K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Indivior PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -11,000,000 to -348,000,000, a change of -337,000,000.
- Net income of 2,000,000 contributed positively to equity growth.
- Share repurchases of 173,000,000 reduced equity.
- New share issuances of 3,000,000 increased equity.
- Other comprehensive income increased equity by 1,323,000,000.
- Other factors decreased equity by 1,492,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX2.00 Million | +0.57% |
| Share Repurchases | GBX173.00 Million | -49.71% |
| Share Issuances | GBX3.00 Million | +0.86% |
| Other Comprehensive Income | GBX1.32 Billion | +380.17% |
| Other Changes | GBX-1.49 Billion | -428.74% |
| Total Change | GBX- | % |
Book Value vs Market Value Analysis
This analysis compares Indivior PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | GBX1.72 | GBX1238.00 | x |
| 2012-12-31 | GBX0.98 | GBX1238.00 | x |
| 2013-12-31 | GBX-0.46 | GBX1238.00 | x |
| 2014-12-31 | GBX-3.28 | GBX1238.00 | x |
| 2015-12-31 | GBX-1.90 | GBX1238.00 | x |
| 2016-12-31 | GBX-1.98 | GBX1238.00 | x |
| 2017-12-31 | GBX-1.36 | GBX1238.00 | x |
| 2018-12-31 | GBX0.44 | GBX1238.00 | x |
| 2019-12-31 | GBX1.39 | GBX1238.00 | x |
| 2020-12-31 | GBX0.53 | GBX1238.00 | x |
| 2021-12-31 | GBX1.34 | GBX1238.00 | x |
| 2022-12-31 | GBX0.35 | GBX1238.00 | x |
| 2023-12-31 | GBX-0.08 | GBX1238.00 | x |
| 2024-12-31 | GBX-2.62 | GBX1238.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Indivior PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.17%
- • Asset Turnover: 0.90x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (68.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 241.73% | 48.96% | 2.24x | 2.20x | GBX588.60 Million |
| 2012 | 418.62% | 45.33% | 2.40x | 3.84x | GBX592.50 Million |
| 2013 | 0.00% | 37.66% | 2.85x | 0.00x | GBX464.60 Million |
| 2014 | 0.00% | 36.14% | 1.49x | 0.00x | GBX450.50 Million |
| 2015 | 0.00% | 22.49% | 1.08x | 0.00x | GBX255.90 Million |
| 2016 | 0.00% | 3.31% | 0.88x | 0.00x | GBX64.50 Million |
| 2017 | 0.00% | 5.31% | 0.76x | 0.00x | GBX78.30 Million |
| 2018 | 416.67% | 27.36% | 0.65x | 23.44x | GBX268.40 Million |
| 2019 | 64.11% | 17.07% | 0.48x | 7.90x | GBX113.10 Million |
| 2020 | -180.49% | -22.87% | 0.42x | 18.67x | GBX-156.20 Million |
| 2021 | 100.99% | 25.92% | 0.43x | 9.02x | GBX184.70 Million |
| 2022 | -103.92% | -5.88% | 0.51x | 34.69x | GBX-58.10 Million |
| 2023 | 0.00% | 0.18% | 0.56x | 0.00x | GBX3.10 Million |
| 2024 | 0.00% | 0.17% | 0.90x | 0.00x | GBX36.80 Million |
Industry Comparison
This section compares Indivior PLC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,115,510,138
- Average return on equity (ROE) among peers: -3.15%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Indivior PLC (INDV) | GBX-258.00 Million | 241.73% | N/A | $187.94K |
| Animalcare Group Plc (ANCR) | $78.80 Million | -0.10% | 0.40x | $23.67K |
| Alliance Pharma plc (APH) | $16.63 Million | 24.70% | 2.42x | $42.55K |
| Beximco Pharmaceuticals Limited (BXP) | $32.80 Billion | 10.72% | 0.53x | $31.61K |
| Celadon Pharmaceuticals PLC (CEL) | $6.41 Million | -74.61% | 0.03x | $1.12K |
| Eco Animal Health Group Plc (EAH) | $9.77 Million | 20.11% | 0.69x | $8.46K |
| Hellenic Dynamics PLC (HELD) | $-102.20K | 0.00% | 0.00x | $1.10 |
| N4 Pharma PLC (N4P) | $7.54 Million | 9.68% | 0.74x | $632.90 |
| Provexis plc (PXS) | $7.58 Million | -15.68% | 0.05x | $3.45K |